Page 15 - Read Online

Wang et al. Hepatoma Res 2018;4:14 I http://dx.doi.org/10.20517/2394-5079.2018.16 Page 9 of 10

Cattral MS, Greig PD, Kachura J, Cleary SP, Sapisochin G. Liver transplantation is equally effective as a salvage therapy for patients
with hepatocellular carcinoma recurrence following radiofrequency ablation or liver resection with curative intent. Ann Surg Oncol
2018;25:991-9.
41. Perea Del Pozo E, Bernal Bellido C, Sendin Matin M, Cepeda Franco C, Alamo Martinez JM, Suarez Artacho G, Marin Gomez LM,
Padillo Ruiz J, Gomez Bravo MA. Recurrent hepatocellular carcinoma after liver transplantation: analysis of risk factors. Transplant
Proc 2016;48:2990-3.
42. Erridge S, Pucher PH. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg
2017;104:1433-42.
43. Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular
carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2017;19:3-9.
44. Wang DY, Liu L, Qi XS, Su CP, Chen X, Liu X, Chen J, Li HY, Guo XZ. Hepatic re-resection versus transarterial chemoembolization
for the treatment of recurrent hepatocellular carcinoma after initial resection: a systematic review and meta-analysis. Asian Pac J
Cancer Prev 2015;16:5573-8.
45. Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver
transplantation? J Surg Res 2016;200:122-30.
46. Zhang X, Li C, Wen T. Outcomes of salvage liver transplantation and re-resection/radiofrequency ablation for intrahepatic recurrent
hepatocellular carcinoma: a new surgical strategy based on recurrence pattern. Dig Dis Sci 2018;63:502-14.
47. Hao S, Fan P, Chen S, Tu C, Wan C. Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery
in patients with hepatocellular carcinoma. J Gastrointest Surg 2017;21:312-20.
48. Zhang X, Li C, Wen T, Yan L, Li B, Yang J, Wang W, Xu M, Lu W, Jiang L. Appropriate treatment strategies for intrahepatic recurrence
after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J
Gastroenterol Hepatol 2015;27:933-40.
49. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC, Sung JL. Clonal origin of recurrent
hepatocellular carcinomas. Gastroenterology 1989;96:527-9.
50. Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular
carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 1999;29:1446-52.
51. Liang XH. Clonal origin of intrahepatic recurrence after resection of hepatocellular carcinoma. Chin J Oncol 1991;13:2-4.
52. Kuo SH, Sheu JC, Chen DS, Sung JL, Lin CC, Hsu HC. DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by
Feulgen-DNA analysis. Liver 1987;7:359-63.
53. Nagasue N, Kohno H, Chang YC, Yamanoi A, Kimoto T, Takemoto Y, Nakamura T. DNA ploidy pattern in synchronous and
metachronous hepatocellular carcinomas. J Hepatol 1992;16:208-14.
54. Hsu HC, Peng SY, Lai PL, Sheu JC, Chen DS, Lin LI, Slagle BL, Butel JS. Allelotype and loss of heterozygosity of p53 in primary and
recurrent hepatocellular carcinomas. A study of 150 patients. Cancer 1994;73:42-7.
55. Shi JY, Xing Q, Duan M, Wang ZC, Yang LX, Zhao YJ, Wang XY, Liu Y, Deng M, Ding ZB, Ke AW, Zhou J, Fan J, Cao Y, Wang J, Xi R,
Gao Q. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget 2016;7:2867-77.
56. Cong WM. The status and thinking of clinicopathological study of multiple nodular hepatocellular carcinoma. Available from: http://
oversea.cnki.net/kcms/detail/detail.aspx?recid=&FileName=ZGKA201510001011&DbName=CPFD2016&DbCode=CPFD [Last
accessed on 24 May 2018].
57. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
58. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol 2012;56:908-43.
59. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
60. Wada H, Eguchi H, Noda T, Ogawa H, Yamada D, Tomimaru Y, Tomokuni A, Asaoka T, Kawamoto K, Gotoh K, Marubashi S,
Umeshita K, Nagano H, Doki Y, Mori M. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple
hepatocellular carcinoma. Surgery 2016;160:1227-35.
61. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for
selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 2014;260:329-40.
62. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi
E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it
adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 2013;257:929-37.
63. Qin HG, Zhong JH, Xiang BD, Wu FX, Peng NF, You XM, Yuan WP, Gong WF, Ma L, Li LQ. Comparison of the prognosis after hepatic
resection for patients with Barcelona Clinical Liver Cancer stage B hepatocellular carcinoma. Natl Med J China 2016;96:3384-8.
64. Zhou YD, Li HK, Cui YL, Zhang T, Li Q. The indications for hepatectomy for multinodular hepatocellular carcinoma: experience from
a single institution. Dig Surg 2015;32:82-9.
65. Ciria R, Lopez-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllon MD, Luque A, Zurera L, Espejo JJ, Rodriguez-Peralvarez M,
Montero JL, de la Mata M, Briceño J. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: modern
surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol 2015;41:1153-61.
66. Guo Z, Zhong Y, Hu B, Jiang JH, Li LQ, Xiang BD. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma
within Milan criteria: a propensity score matching analysis. Medicine 2017;96:e8933.
67. Huang L, Li J, Yan J, Cao J, Liu C, Zhang X, Wu M, Yan Y. Early recurrence after curative resection in oligonodular hepatocellular